Plasma circulating microbial markers for early screening of gastric cancer and application thereof
By combining plasma circulating microbial biomarkers and Low Pass WGS technology, a machine learning model was constructed, which solved the problems of invasiveness and low sensitivity of existing gastric cancer screening methods, achieving efficient and low-cost early gastric cancer screening and improving diagnostic accuracy.
Patent Information
- Application Number
- CN202510958619.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-11
- Publication Date
- 2026-05-26
- Estimated Expiration
- 2045-07-11
AI Technical Summary
Existing gastric cancer screening methods, such as endoscopy, imaging examinations, and serum biomarker testing, are invasive, have low sensitivity or low specificity, and are difficult to meet the needs of large-scale early screening. Furthermore, existing ctDNA testing is costly and susceptible to wild-type DNA interference, and traditional microbial biomarkers, such as Helicobacter pylori testing, lack specificity.
A combination of circulating plasma microbial biomarkers, including 10 microorganisms such as Raulella solanaceae, Staphylococcus aureus, Alternaria alternata, and Porphyromonas gingivalis, was used in conjunction with Low Pass WGS technology to construct a machine learning model for gastric cancer diagnosis. Early screening was performed by detecting the relative abundance of these microorganisms.
It enables high-sensitivity and high-specificity early screening of gastric cancer under low-depth sequencing conditions, reduces detection costs, effectively distinguishes gastric cancer patients from healthy individuals, and improves the early diagnosis rate.